Current Cardiology Reports

, Volume 1, Issue 3, pp 244–250 | Cite as

Combination drug therapy for combined hyperlipidemia

  • John R. Guyton


Combination therapy for hyperlipidemia, especially combined hyperlipidemia, may have advantages over single drug therapy, affording better improvement in lipoprotein risk factors and possibly better prevention of atherothrombotic events. Although preliminary experience has been gained using treatment combinations of niacin with statins, and fibrates with statins, few studies have focused on angiographic or clinical outcomes. Both of these treatment combinations increase the risk of drug-induced myopathy and rhabdomyolysis. Current estimates of myopathy incidence are much lower than original estimates, but the relative safety of combined therapy might depend upon employing low or moderate statin doses. Safety depends critically upon educating the patient to respond appropriately to muscle symptoms, to intercurrent illness, and to concurrent use of certain other medications. Other useful drug combinations include those derived by addition of fish oil, bile acid binding resins, or stanol esters, as well as nonstatin combinations such as niacin-resin or fibrate-niacin.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and recommended reading

  1. 1.
    Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344:1383–1389.CrossRefGoogle Scholar
  2. 2.
    Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237–1245.PubMedCrossRefGoogle Scholar
  3. 3.
    The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. J Am Med Assoc. 1975, 231:360–381.CrossRefGoogle Scholar
  4. 4.
    Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc. 1984, 251:351–374.CrossRefGoogle Scholar
  5. 5.
    Carlson LA, Oro L: Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis. 1973, 18:1–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Morgan JM, Capuzzi DM, Guyton JR, et al.: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Therapeut. 1996, 1:195–202.Google Scholar
  7. 7.
    Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998, 47:1097–1104.PubMedCrossRefGoogle Scholar
  8. 8.
    Knopp RH, Ginsberg J, Albers JJ, et al.: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985, 34:642–650.PubMedCrossRefGoogle Scholar
  9. 9.
    Davignon J, Roederer G, Montigny M, et al.: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994, 73:339–345.PubMedCrossRefGoogle Scholar
  10. 10.
    McKenney JM, Proctor JD, Harris S, Chinchili VM: A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc. 1994, 271:672–677.CrossRefGoogle Scholar
  11. 11.
    • Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998, 82:737–743.PubMedCrossRefGoogle Scholar

A new, better-tolerated niacin formulation (Niaspan) was used in combination with statins in 53 patients, giving enhanced LDL lowering and HDL raising. Although Niaspan is an extended-release niacin, hepatic safety appears well documented

  1. 12.
    • Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol. 1998, 82:82U-84U.PubMedCrossRefGoogle Scholar

A more complete compilation of niacin-statin studies is given, as well as extension of the Niaspan-statin data to 165 patients

  1. 13.
    Capuzzi DM, Guyton JR, Morgan JM, et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998, 82:74U-81U.PubMedCrossRefGoogle Scholar
  2. 14.
    Merck & Company: Product information for Mevacor (lovastatin). In Physician’s Desk Reference. Montvale, New Jersey: Medical Economics Company; 1996:1701.Google Scholar
  3. 15.
    Reaven P, Witztum JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988, 109:597–598.PubMedGoogle Scholar
  4. 16.
    Cooke HM: Lovastatin- and niacin-induced rhabdomyolysis. Hospital Pharmacy. 1994, 29:33–34.Google Scholar
  5. 17.
    Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978, 40:1069–1118.Google Scholar
  6. 18.
    Parke-Davis: Product information for Lopid (gemfibrozil). In Physician’s Desk Reference. Montvale, New Jersey: Medical Economics Company; 1999.Google Scholar
  7. 19.
    Rubins HB, Robins SJ, Collins D: The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol. 1996, 78:572–575.PubMedCrossRefGoogle Scholar
  8. 20.
    Glueck CJ, Oakes N, Speirs J, et al.: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992, 70:1–9.PubMedCrossRefGoogle Scholar
  9. 21.
    Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc. 1990, 264:71–75.CrossRefGoogle Scholar
  10. 22.
    Smith AF, Macfie WG, Oliver MF: Clofibrate, serum enzymes, and muscle pain. Br Med J. 1970, 2:86–88.PubMedGoogle Scholar
  11. 23.
    Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med. 1991, 151:1873–1874.PubMedCrossRefGoogle Scholar
  12. 24.
    Harris WS: Dietary fish oil and blood lipids. Curr Opin Lipidol 1996, 7:3–7.PubMedCrossRefGoogle Scholar
  13. 25.
    Sprecher DL, Abrams J, Allen JW, et al.: Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med. 1994, 120:537–543.PubMedGoogle Scholar
  14. 26.
    East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988, 109:25–32.PubMedGoogle Scholar
  15. 27.
    Gordon DJ, Knoke J, Probstfield JL, et al.: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986, 74:1217–1225.PubMedGoogle Scholar
  16. 28.
    Brown BG, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.PubMedCrossRefGoogle Scholar
  17. 29.
    Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995, 333:1308–1312.PubMedCrossRefGoogle Scholar
  18. 30.
    Pasternak RC, Brown LE, Stone PH, et al.: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. A randomized, placebo-controlled trial. Ann Intern Med. 1996, 125:529–540.PubMedGoogle Scholar
  19. 31.
    Sacks FM, Pasternak RC, Gibson CM, et al.: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet. 1994, 344:1182–1186.PubMedCrossRefGoogle Scholar
  20. 32.
    Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988, 223:405–418.PubMedCrossRefGoogle Scholar
  21. 33.
    Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc. 1990, 264:3007–3012.CrossRefGoogle Scholar
  22. 34.
    Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc. 1987, 257:3233–3240.CrossRefGoogle Scholar
  23. 35.
    Brown BG, Bardsley J, Poulin D, et al.: Moderate dose, threedrug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997, 80:111–115.PubMedCrossRefGoogle Scholar
  24. 36.
    Jacobson TA, Chin MM, Fromell GJ, et al.: Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994, 74:149–154.PubMedCrossRefGoogle Scholar
  25. 37.
    O’Keefe JH, Jr., Harris WS, Nelson J, Windsor SL: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995, 76:480–484.PubMedCrossRefGoogle Scholar
  26. 38.
    Gardner SF, Schneider EF, Granberry MC, Carter IR: Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996, 16:419–423.PubMedGoogle Scholar
  27. 39.
    Gardner SF, Marx MA, White LM, et al.: Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother. 1997, 31:677–682.PubMedGoogle Scholar
  28. 40.
    Vacek JL, Dittmeier G, Chiarelli T, et al.: Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 1995, 76:182–184.PubMedCrossRefGoogle Scholar
  29. 41.
    Wiklund O, Angelin B, Bergman M, et al.: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993, 94:13–20.PubMedCrossRefGoogle Scholar
  30. 42.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al.: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997, 80:608–613.PubMedCrossRefGoogle Scholar
  31. 43.
    Ellen RL, McPherson R: Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998, 81:60B-65B.PubMedCrossRefGoogle Scholar
  32. 44.
    Iliadis EA, Rosenson RS: Long-term safety of pravastatingemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999, 22:25–28.PubMedCrossRefGoogle Scholar
  33. 45.
    Zambon D, Ros E, Rodriguez-Villar C, et al.: Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism. 1999, 48:47–54.PubMedCrossRefGoogle Scholar
  34. 46.
    • Kayikcioglu M, Ozerkan F, Soydan I: Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol. 1999, 83:1135–1137.PubMedCrossRefGoogle Scholar

The data suggest that giving simvastatin and fenofibrate on alternate days may be just as effective in correcting dyslipidemia as giving twice the treatment doses (the same doses of both drugs every day)

  1. 47.
    Contacos C, Barter PJ, Sullivan DR: Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993, 13:1755–1762.PubMedGoogle Scholar
  2. 48.
    Davidson MH, Macariola-Coad JR, McDonald AM, et al.: Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 1997, 80:797–798.PubMedCrossRefGoogle Scholar
  3. 49.
    Spencer GA, Wirebaugh S, Whitney EJ: Effect of a combination of gemfibrozil and niacin on lipid levels. J Clin Pharmacol 1996, 36:696–700.PubMedGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • John R. Guyton
    • 1
  1. 1.Department of MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations